These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 12579899)

  • 1. [Detection of crystal polymorphs of nateglinide by DSC].
    Lin KJ; Chen W; You QD
    Yao Xue Xue Bao; 2002 Jan; 37(1):46-9. PubMed ID: 12579899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the nateglinide polymorphic purity through DSC.
    Bruni G; Berbenni V; Milanese C; Girella A; Cardini A; Lanfranconi S; Marini A
    J Pharm Biomed Anal; 2011 Apr; 54(5):1196-9. PubMed ID: 21216126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new crystal form of nateglinide.
    Li G; Su GQ; Xu QW; Zhu CQ
    Yao Xue Xue Bao; 2001 Jul; 36(7):532-4. PubMed ID: 12585087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility studies of nateglinide with excipients in immediate release tablets.
    Pani NR; Nath LK; Acharya S
    Acta Pharm; 2011 Jun; 61(2):237-47. PubMed ID: 21684850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.
    Maggi L; Bruni G; Maietta M; Canobbio A; Cardini A; Conte U
    Int J Pharm; 2013 Sep; 454(1):562-7. PubMed ID: 23867985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating relative stability of polymorphs by generation of configurational free energy phase diagram.
    Upadhyay P; Dantuluri AK; Kumar L; Bansal AK
    J Pharm Sci; 2012 May; 101(5):1843-51. PubMed ID: 22344848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New solid modifications of nateglinide.
    Bruni G; Berbenni V; Milanese C; Girella A; Cardini A; Lanfranconi S; Marini A
    J Pharm Biomed Anal; 2010 Apr; 51(5):1054-9. PubMed ID: 20022441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of semicrystalline polymers on self-emulsifying solid dispersions of nateglinide: in vitro and in vivo evaluation.
    Swain RP; Subudhi BB
    Drug Dev Ind Pharm; 2018 Jan; 44(1):56-65. PubMed ID: 28845687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermodynamic relationships between nateglinide polymorphs.
    Bruni G; Berbenni V; Milanese C; Girella A; Cardini A; Viganò E; Lanfranconi S; Marini A
    J Pharm Biomed Anal; 2009 Dec; 50(5):764-70. PubMed ID: 19570642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation.
    Wairkar S; Gaud R; Jadhav N
    J Pharm Pharmacol; 2017 Sep; 69(9):1099-1109. PubMed ID: 28590055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method.
    Bashir S; Nazir I; Khan H; Alamgeer ; Asad M; ul Hassnain F; Qamar S
    Pak J Pharm Sci; 2013 Nov; 26(6):1229-35. PubMed ID: 24191331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-Amorphous Combination of Nateglinide-Metformin Hydrochloride for Dissolution Enhancement.
    Wairkar S; Gaud R
    AAPS PharmSciTech; 2016 Jun; 17(3):673-81. PubMed ID: 26314243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification by p-aminobenzoic acid (PABA)-affinity chromatography and the functional reconstitution of the nateglinide/H+ cotransport system in the rat intestinal brush-border membrane.
    Saito Y; Itagaki S; Kubo S; Kobayashi M; Hirano T; Iseki K
    Biochem Biophys Res Commun; 2006 Feb; 340(3):879-86. PubMed ID: 16403453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the nateglinide polymorphism structure and the drug effect.
    Li G; Chen JY; Lü GL; Xu QW
    Yao Xue Xue Bao; 2005 Oct; 40(10):958-60. PubMed ID: 16408818
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus.
    Tamura M; Shiba S; Kudo N; Kawashima Y
    Chirality; 2010 Jan; 22(1):92-8. PubMed ID: 19387990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphs of 1,1-bis(4-hydroxyphenyl)cyclohexane and multiple Z' crystal structures by melt and sublimation crystallization.
    Sarma B; Roy S; Nangia A
    Chem Commun (Camb); 2006 Dec; (47):4918-20. PubMed ID: 17136246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the L-enantiomer of nateglinide in pharmaceutical formulations by micellar electrokinetic chromatography.
    Phan TD; Nguyen NH; Kim DJ; Lee YJ; Choi SH; Kim KH
    Arch Pharm Res; 2010 Dec; 33(12):2017-24. PubMed ID: 21191768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels.
    Chachin M; Yamada M; Fujita A; Matsuoka T; Matsushita K; Kurachi Y
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1025-32. PubMed ID: 12604678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calorimetric and x-ray diffraction studies of rye glucocerebroside mesomorphism.
    Lynch DV; Caffrey M; Hogan JL; Steponkus PL
    Biophys J; 1992 May; 61(5):1289-300. PubMed ID: 1600084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.